The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Chylopericardium and chylous effusions during treatment with selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC).
 
Alvaro Paula
Honoraria - Pfizer
 
Ximeng Liu
No Relationships to Disclose
 
Simon Heeke
Employment - Marker Therapeutics (I)
Honoraria - Qiagen
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - AstraZeneca; Guardant Health
Patents, Royalties, Other Intellectual Property - Patent on the Treatment of Lung Cancer
Travel, Accommodations, Expenses - Roche
 
Kyle Concannon
No Relationships to Disclose
 
Monique Nilsson
Patents, Royalties, Other Intellectual Property - Spectrum Pharmaceuticals
 
Yasir Elamin
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Lilly; Sanofi; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; GlaxoSmithKline; Hengrui Pharmaceutical; Janssen; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; Nexus Health Systems; Pneuma Respiratory; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - DAVA Pharmaceuticals; IDEOlogy Health; MJH Life Sciences
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding subtyping of SCLC lung cancer.